Recent Updates
Recently added Catalysts
REGN

Regeneron Reports Second Quarter Financial and Operating Results

Key Takeaway: Regeneron Reports Second Quarter Financial and Operating Results

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema

Full Press Release Details

Regeneron Reports Second Quarter Financial and Operating Results.
Last updated: Aug 1, 2007